Leap Therapeutics Inc (NASDAQ:LPTX) stock soared 21% on Monday. This rise comes after the company announced that it would present initial results from theDisTinGuish study.
The study is a Phase IIa clinical trial for DKN-01, the company’s (DKK1) antibody used with tislelizumab and chemotherapy to treat patients with gastroesophageal junction or gastric cancer.
The company has found that DKN-01, when combined with chemotherapy andtislelizumab as the first-line drug for gastroesophageal junction cancer, had high efficacy. In patients who were given a full round of DKN-01 therapy, their overall response rates (ORR) were 68.2%. The ORR inpatients with high DKK1 was 90% and 56% in low DKK1 patients.
They also found that the study’s overall intent to treat the population, ORR seen, was 60%. The ORR was 75% in patients with high DKK1 and 56% in those with low DKK1.
So far, 13 patients had a partial response, six had the best response of stable disease, one could not be evaluated for a response, two were pending their first tumour assessment, and three could not finish a full round of therapy.
Market Reaction:
On Monday, LPTX stock surged 21% at $1.77 with more than 63.07 million shares, compared to its average volume of 566K shares. The stock has moved within a range of $1.6600 – 1.9200 after opening the trade at $1.87.
